معرفی
Dr. Oliver Sutcliffe is a Reader and Director of MANDRAKE at Manchester Metropolitan University's School of Natural Sciences. He is a research-active pharmaceutical chemist specializing in the synthesis, analysis, and harm reduction of illicit drugs and New Psychoactive Substances (NPS). His work has positioned Manchester Met at the forefront of coordinated, interdisciplinary research to combat global drug challenges, with his research being embedded into policy documents such as the GM Drug & Alcohol Strategy (2019-21) and the Greater Manchester Police Drug Strategy (2024-2025).
His educational background includes:
- BSc (Hons) in Chemical Sciences from the University of Liverpool
- PhD in Synthetic Organic Chemistry from the University of Liverpool
- MSc in Pharmaceutical Analysis from the University of Strathclyde
Dr. Sutcliffe's research focuses on the synthesis and characterization of illicit drugs and NPS, development of field-deployable chromatographic and spectroscopic techniques for drug analysis, application of NMR to routine drug testing, biological evaluation of psychoactive drugs' health effects, and promoting harm reduction through rapid chemical analysis. His work bridges analytical chemistry, pharmacology, and public health to address real-world drug challenges.
His recent publications reveal a strong focus on analyzing synthetic cannabinoids in vaping products, developing portable detection technologies, and understanding emerging drug trends. His research has significant practical applications in law enforcement, public health policy, and harm reduction strategies, particularly through his leadership of the MANDRAKE initiative.
His scientific awards include:
- RSC Analytical Science Horizon Prize: Sir George Stokes Prize Winner (2025)
- Fellow of the Royal Society of Chemistry (FRSC) (August 2016)
- Fellow of the Higher Education Academy (FHEA)
Dr. Sutcliffe has supervised eleven PhD students and eleven MRes/MPhil students to completion as Principal Supervisor, and currently supervises two additional PGR students. His research has attracted significant funding, including a £1.3M EPSRC grant focusing on portable device development for synthetic cannabinoid detection. His interdisciplinary approach has led to collaborations with police, public authorities, healthcare providers, and industry partners across multiple sectors.
As Director of MANDRAKE (Manchester Drug Analysis and Knowledge Exchange), he leads England's first publicly-funded permanent city-centre based testing and harm reduction facility, operating since 2016. This initiative supports open science and agencies working toward safeguarding public health and wellbeing through rapid chemical analysis of substances.
